Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction

Journal of the American College of Cardiology

Volumn 36, Issue 4, 2000, Pages 1202-1209

  Morishima, Itsuro ^a   Sone, Takahito ^b   Okumura, Kenji ^a   Tsuboi, Hideyuki ^b   Kondo, Junichiro ^b   Mukawa, Hiroaki ^b   Matsui, Hideo ^a   Toki, Yukio ^a   Ito, Takayuki ^a   Hayakawa, Tetsuo ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CINEANGIOGRAPHY; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECANALIZATION; RISK FACTOR; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CAUSE OF DEATH; CINEANGIOGRAPHY; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMAN; JAPAN; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; VENTRICULAR FUNCTION, LEFT;

EID: 0033809487     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00865-2     Document Type: Article

References (37)

1. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction
2. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
3. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction
4. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty
5. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction
6. The no-reflow phenomenon
7. The 'no-reflow' phenomenon after temporary coronary occlusion in the dog
8. Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction. New insights using myocardial contrast echocardiography
9. Scintigraphic evidence of the 'no reflow' phenomenon in human beings after coronary thrombolysis
10. Assessment of 'microvascular no-reflow phenomenon' using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction
11. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine
12. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention
13. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction
14. Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction
15. The pattern of alteration in flow velocity in the recanalized artery is related to left ventricular recovery in patients with acute infarction and successful direct balloon angioplasty
16. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction
17. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction. Myocardial blush grade
18. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications
19. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors
20. Cardiovascular death and left ventricular remodeling two years after myocardial infarction. Baseline predictors and impact of long-term use of captopril: Information from the Survival and Ventricular Enlargement (SAVE) trial
21. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography
22. Stabilization of human brain natriuretic peptide in blood samples
23. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog
24. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction. Possible implications for leukocyte aggregation and microvascular plugging
25. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction
26. Left ventricular remodeling after myocardial infarction: A corollary to infarct expansion
27. Influence of infarctzone viability on left ventricular remodeling after acute myocardial infarction
28. Collagen and ventricular remodeling after acute myocardial infarction: Concepts and hypotheses
29. Matrix metalloproteinases and cardiovascular disease
30. Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart
31. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide
32. Plasma brain natriuretic peptide as an indicator for angiotensin-converting enzyme inhibition after myocardial infarction
33. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide
34. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction
35. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
36. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction
37. Extended mortality benefit of early postinfarction reperfusion